GlassScriptPhysician profile
Patrick L Elliott
NPI 1841270949
$2,246.88
in general payments reported to CMS, 2019-2025
17 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $38.58 · 2021: $83.03 · 2022: $249 · 2023: $241 · 2024: $935 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833 · Consulting Fee: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.08 |
| Consulting Fee | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $935.25 | 2024 | Ioban 2, 3m Ioban, Prevena |
| Davol INC. | $161.92 | 2025 | Phasix Mesh |
| Medtronic, INC. | $151.67 | 2025 | Signia |
| Organogenesis INC. | $143.45 | 2025 | Apligraf, Puraply Wound Matrix, Affinity |
| Stryker Corporation | $135.82 | 2022 | |
| Allergan, INC. | $114.32 | 2019 | |
| Smith+Nephew, INC. | $110.25 | 2019 | |
| Kerecis Limited | $99.51 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Takeda Pharmaceuticals U.S.A., INC. | $92.15 | 2022-2023 | Gattex |
| Integra Lifesciences Corporation | $84.79 | 2021-2023 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Kci USA, INC. | $72.73 | 2023 | Abthera Advance |
| Bioventus LLC | $45.20 | 2022 | |
| Baxter Healthcare | $21.70 | 2021 | |
| Innocoll Pharmaceuticals Limited | $20.86 | 2022 | |
| Amgen INC. | $19.40 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $19.18 | 2020 | |
| Olympus America INC. | $18.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.